EP4055005A1 - Composition liquide de melphalan - Google Patents

Composition liquide de melphalan

Info

Publication number
EP4055005A1
EP4055005A1 EP20886165.8A EP20886165A EP4055005A1 EP 4055005 A1 EP4055005 A1 EP 4055005A1 EP 20886165 A EP20886165 A EP 20886165A EP 4055005 A1 EP4055005 A1 EP 4055005A1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
melphalan
pharmaceutically acceptable
stable
liquid pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20886165.8A
Other languages
German (de)
English (en)
Other versions
EP4055005A4 (fr
Inventor
Nimitt CHOKSHI
Rushabh Shah
Nagnath G GOBADE
Kamal Kumar Upadhyay
Alex K George
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intas Pharmaceuticals Ltd
Original Assignee
Intas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intas Pharmaceuticals Ltd filed Critical Intas Pharmaceuticals Ltd
Publication of EP4055005A1 publication Critical patent/EP4055005A1/fr
Publication of EP4055005A4 publication Critical patent/EP4055005A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/44—Stabilisation; Use of additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Definitions

  • the present invention related to a stable liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients, wherein the said stable liquid pharmaceutical composition is first diluted with a diluent vehicle to provide a stable ready to dilute pharmaceutical composition of melphalan or its pharmaceutically acceptable salts thereof.
  • the said stable ready to dilute pharmaceutical composition is further diluted to obtain a final diluted melphalan composition before administering to the patient in need thereof.
  • the present invention provides process for the preparation of the said composition and its use for the treatment of multiple myeloma.
  • Melphalan is a bifunctional alkylating agent, which is a phenylalanine derivative of nitrogen mustard. It is also known as L-phenylalanine mustard, phenylalanine mustard, L-PAM, or L-sarcolysin which is chemically known 4-[bis(2- chloroethyl)amino]-L-phenylalanine and molecular formula is C13H18C12N2O2.
  • FIG. 1 Melphalan Melphalan primarily degrades through sequential hydrolysis to the hydrolytic degradants monohydroxymelphalan and dihydroxymelphalan. Individual hydrolysis products, monohydroxymelphalan and dihydroxymelphalan, are observed as the main degradants in room temperature stored samples, along with small quantities of melphalan dimer. To overcome the hydrolytic degradation of Melphalan and preparing commercially available products, following approaches appear to have been made:
  • US4997651 patent discloses two-component pharmaceutical formulation of Melphalan comprising freeze-dried Melphalan hydrochloride and a solvent- diluent comprising a citrate, propylene glycol and ethanol.
  • US2013131174 patent application discloses a solid lyophilized composition of Melphalan hydrochloride having a pH between 4 and 6.
  • WO2017085696 patent application disclose a stable, parenteral formulation comprising Melphalan and cyclodextrin or its derivative thereof, wherein the formulation is free of propylene glycol.
  • US2018193255 patent application disclose ready to use liquid parenteral formulation comprising of Melphalan and pharmaceutically acceptable adjuvants thereof.
  • Commercially available parenteral preparations of Melphalan are manufactured by lyophilization.
  • Melphalan is commercially available in tablet form (Alkeran®) and Injectable form (Alkeran®) and (Evomela®), for the treatment of multiple myeloma.
  • the commercial injectable formulation of Melphalan injectable Alkeran® is supplied as a sterile, nonpyrogenic, freeze-dried powder. Each single use vial contains Melphalan hydrochloride equivalent to 50 mg Melphalan and 20 mg povidone. Alkeran® is reconstituted using the sterile diluent containing sodium citrate, propylene glycol, ethanol and water for injection to a volume of 10 mL.
  • the Alkeran® to be infused must be diluted to not more than 0.45 mg/ml in normal saline and infused over 15 minutes.
  • the diluted product needs to be administered within 60 minutes from time of reconstitution.
  • the said reconstituted solution cause precipitation while store at 2- 8 °C. Further slow addition of diluent or delay in shaking during reconstitution which resulting in formation of insoluble solid particles in solution.
  • the commercially available formulation of melphalan injectable Evomela® (50mg/vial) is a lyophilized composition and comprises of Melphalan and Betadex sulfobutyl ether sodium.
  • the lyophilized composition must be reconstituted using 0.9% sodium chloride solution.
  • the reconstituted solution is stable for 24 hours at refrigerated temperature without any precipitation due to the high solubility and stable for 1 hour at room temperature. On further dilution in sodium chloride, the solution is stable for 4 hours at room temperature in addition to the 1 hour following reconstitution.
  • the inventors of the present invention have developed a stable liquid pharmaceutical composition comprising Melphalan or its pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients, wherein the said pharmaceutical composition of Melphalan is first diluted with a diluent vehicle to provide a stable ready to dilute pharmaceutical composition of melphalan or its pharmaceutically acceptable salts thereof.
  • the said stable ready to dilute pharmaceutical composition has improved stability and can be stored for at least 72 hours at 2-8 °C without any precipitation.
  • the said stable ready to dilute pharmaceutical composition is further diluted in 0.9% sodium chloride or 5% dextrose to obtain a final diluted melphalan composition and wherein the said final diluted melphalan composition is stable for at least 2 hours when stored at room temperature.
  • the primary object of the present invention is to provide a stable liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.
  • Another object of the present invention is to provide a stable liquid pharmaceutical composition
  • a stable liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof, one or more solvents, one or more antioxidants, sodium chloride and optionally one or more pharmaceutically acceptable excipients.
  • Another object of the present invention is to provide a process for preparation of liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients comprises the step of:
  • step a) dissolving sodium chloride to the clear solution obtained in step a);
  • step b) dissolving one or more antioxidant to the solution obtained in step b);
  • step c) dissolving melphalan or its pharmaceutically acceptable salt in solution obtained in step c) and making up the volume.
  • step d) filtering the solution obtained in step d) and filling the filtered solution in suitable vials.
  • Another object of the present invention is to provide a stable liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof, one or more solvents, one or more antioxidants, sodium chloride and optionally one or more pharmaceutically acceptable excipients, wherein the said liquid pharmaceutical composition is first diluted with a diluent vehicle to provide a stable ready to dilute pharmaceutical composition of melphalan or its pharmaceutically acceptable salt thereof.
  • Another object of the present invention is to provide a stable liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof, one or more solvents, one or more antioxidants, sodium chloride and optionally one or more pharmaceutically acceptable excipients, wherein the said stable liquid pharmaceutical composition is first diluted with a diluent vehicle comprising cyclodextrin derivative, sodium chloride, one or more solvents and optionally buffering agent to provide a stable ready to dilute pharmaceutical composition of melphalan or its pharmaceutically acceptable salt thereof.
  • Another object of the present invention is to provide a stable liquid pharmaceutical composition
  • a stable liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof, one or more solvents, one or more antioxidants, sodium chloride and optionally one or more pharmaceutically acceptable excipients
  • the said stable liquid pharmaceutical composition is first diluted with a diluent vehicle comprising cyclodextrin derivative, sodium chloride, one or more solvents and optionally buffering agent to provide a stable ready to dilute pharmaceutical composition of melphalan or its pharmaceutically acceptable salt thereof, and wherein cyclodextrin derivative is present in a weight ratio of less than 50: 1 relative to the melphalan or its pharmaceutically acceptable salt.
  • Another object of the present invention is to provide a stable liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof, one or more solvents, one or more antioxidants, sodium chloride and optionally one or more pharmaceutically acceptable excipients, wherein the said stable liquid pharmaceutical composition is first diluted with a diluent vehicle comprising cyclodextrin derivative, sodium chloride, one or more solvents and optionally buffering agent to provide a stable ready to dilute pharmaceutical composition of melphalan or its pharmaceutically acceptable salt thereof, wherein the said stable ready to dilute composition is stable for at least 72 hours when stored at 2-8 °C and for at least 1 hour when stored at room temperature (25 °C).
  • Another object of the present invention is to provide a stable liquid pharmaceutical composition
  • a stable liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof, one or more solvents, one or more antioxidants, sodium chloride and optionally one or more pharmaceutically acceptable excipients, wherein the said stable liquid pharmaceutical composition is first diluted with a diluent vehicle to provide a stable ready to dilute pharmaceutical composition, and the said stable ready to dilute composition is further diluted with sodium chloride solution or dextrose solution to obtain final diluted melphalan composition before administering to the patient in need thereof.
  • Another object of the present invention is to provide a stable liquid pharmaceutical composition
  • a stable liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof, one or more solvents, one or more antioxidants, sodium chloride and optionally one or more pharmaceutically acceptable excipients
  • the said stable liquid pharmaceutical composition is first diluted with a diluent vehicle to provide a stable ready to dilute pharmaceutical composition, and the said stable ready to dilute composition is further diluted with 0.9% sodium chloride solution or 5% dextrose solution to obtain final diluted melphalan composition before administering to the patient in need thereof.
  • Another object of the present invention is to provide a stable liquid pharmaceutical composition
  • a stable liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof, one or more solvents, one or more antioxidants, sodium chloride and optionally one or more pharmaceutically acceptable excipients, wherein the said stable liquid pharmaceutical composition is first diluted with a diluent vehicle to obtain a stable ready to dilute pharmaceutical composition, and the said stable ready to dilute pharmaceutical composition is further diluted with 0.9% sodium chloride solution or 5% dextrose solution to obtain a final diluted melphalan composition.
  • Another object of the present invention is to provide a stable liquid pharmaceutical composition
  • a stable liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof, one or more solvents, one or more antioxidants, sodium chloride and optionally one or more pharmaceutically acceptable excipients
  • the said stable liquid pharmaceutical composition is first diluted with a diluent vehicle to obtain a stable ready to dilute pharmaceutical composition
  • the said stable ready to dilute pharmaceutical composition is further diluted with 0.9% sodium chloride solution and 5% dextrose solution to obtain a final diluted melphalan composition
  • the said final diluted melphalan composition is stable for at least 2 hours when stored at 25 °C.
  • Another object of the present invention is to provide a stable liquid pharmaceutical composition
  • a stable liquid pharmaceutical composition comprising Melphalan or its pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients, wherein the said composition does not have more than 7.5% (w/w) of Impurity D, more preferably the said composition does not have more than 2% of Impurity D when stored at 2-8 °C for at least 3 months.
  • Another object of the present invention is to provide a stable liquid pharmaceutical composition
  • a stable liquid pharmaceutical composition comprising Melphalan or its pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients, wherein the said composition does not have more than 7.5% (w/w) of Impurity D, more preferably the said composition does not have more than 2% (w/w) of Impurity D when stored at 25 °C for at least 3 months.
  • Another object of the present invention is to provide a stable liquid pharmaceutical composition
  • a stable liquid pharmaceutical composition comprising Melphalan or its pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients, wherein the said composition does not have more than 1% (w/w) of Impurity G, more preferably the said composition does not have more than 0.6% (w/w) of Impurity G when stored at 2-8 °C for at least 3 months.
  • Another object of the present invention is to provide a stable liquid pharmaceutical composition comprising Melphalan or its pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients, wherein the said composition does not have more than 1% (w/w) of Impurity G, more preferably the said composition does not have more than 0.6% (w/w) of Impurity G when stored at 25 °C for at least 3 months.
  • Another object of the present invention is to provide a stable liquid pharmaceutical composition
  • a stable liquid pharmaceutical composition comprising Melphalan or its pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients, wherein the said composition does not have more than 10% (w/w) of total impurity, more preferably the said composition does not have more than 5% of total impurity when stored at 2-8 °C for at least 3 months.
  • Another object of the present invention is to provide a stable liquid pharmaceutical composition comprising Melphalan or its pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients, wherein the said composition does not have more than 10% (w/w) of total impurity, more preferably the said composition does not have more than 5% of total impurity when stored at 25 °C for at least 3 months.
  • Another object of the present invention is to provide a stable liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients, wherein the said composition is used for the treatment of multiple myeloma.
  • the present invention related to stable liquid pharmaceutical composition
  • stable liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients
  • the said stable liquid pharmaceutical composition is first diluted with a diluent vehicle to provide a stable ready to dilute pharmaceutical composition and the said ready to dilute composition is stable for at least 72 hours when stored at 2-8 °C and for at least 1 hour when stored at room temperature (25 °C) without any precipitation.
  • the said stable ready to dilute pharmaceutical composition is further diluted with sodium chloride solution or dextrose solution to obtain a final diluted melphalan composition before administering to the patient in need thereof.
  • the present invention provides process for the preparation of the said composition and its use for the treatment of multiple myeloma.
  • the present invention related to stable liquid pharmaceutical composition
  • melphalan or its pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.
  • the present invention provides process for the preparation of the said composition and its use for the treatment of multiple myeloma.
  • Melphalan used throughout the specification refers to not only their base per se, but also their other pharmaceutically acceptable salt, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs and pharmaceutically acceptable prodrugs thereof, preferably Melphalan Hydrochloride.
  • liquid pharmaceutical composition refers to a pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof, one or more solvents, one or more antioxidants, sodium chloride and optionally one or more pharmaceutically acceptable excipients.
  • This liquid pharmaceutical composition is first diluted with a diluent vehicle to provide a stable ready to dilute pharmaceutical composition, which is further diluted with sodium chloride or dextrose to obtain final diluted melphalan composition before administering to the patient in the need thereof.
  • pharmaceutically acceptable means salt, carriers, excipients, and other formulation ingredients that are compatible with all other pharmaceutical ingredients of a composition and are not deleterious to an individual treated with composition.
  • diluent vehicle refers to a vehicle composition which is used to first dilute the liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof.
  • the diluent vehicle comprises of cyclodextrin derivative, sodium chloride, one or more solvents and optionally buffering agent.
  • ready to dilute pharmaceutical composition refers to a stable, liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof, which is first diluted with a diluent vehicle comprising cyclodextrin derivative, sodium chloride, one or more solvents and optionally buffering agent to obtain a stable ready to dilute pharmaceutical composition.
  • the said stable ready to dilute pharmaceutical composition is stable for at least 72 hours when stored at 2-8 °C and for at least 1 hour when stored at room temperature (25 °C).
  • final diluted melphalan composition refers to liquid pharmaceutical composition of melphalan diluted with diluent vehicle wherein diluent vehicle contains cyclodextrin derivative, sodium chloride, one or more solvents and optionally buffering agent to obtain stable ready to dilute melphalan composition, wherein the obtained stable ready to dilute melphalan composition is further diluted with sodium chloride solution or dextrose solution to obtain a final diluted melphalan composition, which is administered to the patient in need thereof.
  • stable refers to a pharmaceutical composition in which the active pharmaceutical ingredients melphalan is present in an amount of at least 90% of the original label specified amount for each such ingredient during storage at 2-8 °C and 25 °C.
  • Impurity D of melphalan as used throughout the specification, refers to below structure:
  • Impurity G of melphalan as used throughout the specification, refers to below structure:
  • total impurities of melphalan as used throughout the specification, refers to identified or unidentified degradation product or impurity structurally related with Melphalan which are arising from a manufacturing process or during storage of material.
  • the present invention is to provide a stable liquid pharmaceutical composition
  • a stable liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof and one or more pharmaceutical acceptable excipients.
  • the present invention is to provide a stable liquid pharmaceutical composition
  • a stable liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof, one or more solvents, one or more antioxidants, sodium chloride and optionally one or more pharmaceutically acceptable excipients.
  • the present invention is to provide a process for preparation of liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients comprises the step of:
  • step a) dissolving sodium chloride to the clear solution obtained in step a);
  • step c) dissolving one or more antioxidant to the solution obtained in step b); (d) dissolving melphalan or its pharmaceutically acceptable salt in solution obtained in step c) and making up the volume.
  • step d) filtering the solution obtained in step d) and filling the filtered solution in suitable vials.
  • the one or more solvents can be selected from the group comprising of but not limited to dimethylacetamide (DMA), dimethyl sulfoxide (DMSO), N- methylpyrrolidone, dimethylisosorbide, ethanol, propylene glycol, glycerine, polyethylene alcohol, propylene glycol esters, polyethylene glycols and the like.
  • DMA dimethylacetamide
  • DMSO dimethyl sulfoxide
  • N- methylpyrrolidone N- methylpyrrolidone
  • dimethylisosorbide ethanol
  • propylene glycol glycerine
  • polyethylene alcohol propylene glycol esters
  • polyethylene glycols and the like Preferred solvents are polyethylene glycols (PEG) and propylene glycol.
  • the anti-oxidant can be selected from the group comprising of but not limited to butylated hydroxyanisole, butylated hydroxyltoluene, tocopherol, ethylenediaminetetraacetic acid, monothioglycerol, ascorbic acid and their esters, L-cysteine, parabens, benzyl alcohol, propyl gallate, thioglycolic acid, tartaric acid, citric acid, or mixture thereof. Most preferred anti-oxidant is Monothioglycerol.
  • liquid pharmaceutical composition comprising melphalan HC1, monothioglycerol, sodium chloride, propylene glycol and polyethylene glycol.
  • the present invention is to provide a stable liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof, one or more solvents, one or more antioxidants, sodium chloride and optionally one or more pharmaceutically acceptable excipients, wherein the said stable liquid pharmaceutical composition is first diluted with a diluent vehicle to provide a stable ready to dilute pharmaceutical composition of melphalan or its pharmaceutically acceptable salt thereof.
  • the diluent vehicle comprises cyclodextrin derivative, sodium chloride, one or more solvents and optionally buffering agent.
  • the diluent vehicle may be present in vial or Pre-Filled Syringe (PFS).
  • PFS Pre-Filled Syringe
  • cyclodextrin derivative is present in less than 270 mg/ ml of total volume of diluent vehicle, more preferably less than 250 mg/ml of cyclodextrin, most preferably less than 200 mg/ ml of cyclodextrin of total volume of diluent vehicle.
  • the diluent vehicle having a volume of 9 mL shall contain around 400 mg to 2450 mg, 500 mg to 2250 mg, 600 to 1800 mg of cyclodextrin derivatives of total weight of the diluent vehicle composition.
  • Cyclodextrins (CDs) derivatives are water soluble macrocyclic oligosaccharides with a-D-glucose units linked by a-(l- 4) glycosidic bonds, widely used to solubilize various water insoluble drugs. It is driven by non-covalent interactions such as van der Waals forces, hydrogen bonding and hydrophobic interactions. Additionally, complex formation of CDs with drugs improve stability due to decrease in hydrolysis.
  • the cyclodextrin derivative can be selected from the group comprising of but not limited to a, b and g-cyclodextrin and cyclodextrins modified with alkyl-, hydroxy alkyl, dialkyl-, and sulfoalkyl-ether modified cyclodextrins such as methyl or hydroxypropyl b-cyclodextrins (HPpCD), methyl-and-ethyl-P-cyclodextrin, sulfoalkylether-substituted beta-cyclodextrin, Betadex sulfobutyl ether sodium, sulfobutylether-P-cyclodextrin (SBECD) and the like. Most preferred cyclodextrin is Betadex sulfobutyl ether sodium.
  • sodium chloride may be present in 0.9% of the total weight of the diluent vehicle.
  • the diluent vehicle comprises cyclodextrin derivative, sodium chloride, one or more solvents and optionally buffering agent, wherein the said diluent vehicle is used to dilute the stable liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof, to provide a stable ready to dilute pharmaceutical composition having pH of about 2-5.
  • the diluent vehicle comprises cyclodextrin derivative, sodium chloride, one or more solvents and buffering agent, wherein the said diluent vehicle is used to dilute the liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof, to provide a stable ready to dilute pharmaceutical composition having pH of about 4-5.
  • the said buffering agents are, such as, but not limited to, citrate buffer, acetate buffers, phosphate buffer, amino acids, and the like.
  • Preferred buffers are sodium citrate anhydrous and sodium acetate monohydrate.
  • the diluent vehicle also contains water for injection as a preferred solvent.
  • stable liquid pharmaceutical composition comprising 50 mg/ml of melphalan HC1, which is first diluted with 9 ml of diluent vehicle to provide the 5mg/ml of stable ready to dilute pharmaceutical composition of melphalan or its pharmaceutically acceptable salt.
  • the stable ready to dilute pharmaceutical composition of melphalan or its pharmaceutically acceptable salts has a pH of about 2-5.
  • the stable ready to dilute pharmaceutical composition comprises cyclodextrin derivative, wherein the said cyclodextrin derivative is present in a ratio of less than 50: 1 relative to the melphalan or its pharmaceutically acceptable salt.
  • the present invention is to provide a stable liquid pharmaceutical composition
  • a stable liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof, one or more solvents, one or more antioxidants, sodium chloride and optionally one or more pharmaceutically acceptable excipients
  • the said stable liquid pharmaceutical composition is first diluted with a diluent vehicle to provide a stable ready to dilute pharmaceutical composition of melphalan or its pharmaceutically acceptable salt thereof, wherein the said stable ready to dilute composition is stable for at least 72 hours when stored at 2-8 °C and for at least 1 hour when stored at room temperature (25 °C) .
  • the stable ready to dilute pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt and cyclodextrin derivatives is stable for at least 72 hours when stored at 2-8 °C and for at least 1 hour when stored at room temperature (25 °C), wherein the cyclodextrin derivative is present in a ratio of less than 50:1 relative to the melphalan or its pharmaceutically acceptable salts.
  • the present invention is to provide a stable liquid pharmaceutical composition
  • a stable liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof, one or more solvents, one or more antioxidants, sodium chloride and optionally one or more pharmaceutically acceptable excipients
  • the said stable liquid pharmaceutical composition is first diluted with a diluent vehicle to provide a stable ready to dilute pharmaceutical composition, and the said stable ready to dilute composition is further diluted with sodium chloride solution or dextrose solution to obtain final diluted melphalan composition, which is administered to the patient in need thereof.
  • the stable ready to dilute pharmaceutical composition is further diluted with 0.9% sodium chloride solution or 5% dextrose solution to obtain final diluted melphalan composition, which is administered to the patient in need thereof.
  • the present invention is to provide a stable liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof, one or more solvents, one or more antioxidants, sodium chloride and optionally one or more pharmaceutically acceptable excipients, wherein the said stable liquid pharmaceutical composition is first diluted with a diluent vehicle to provide a stable ready to dilute pharmaceutical composition, and the said stable ready to dilute composition is further diluted with 0.9% sodium chloride solution or 5% dextrose solution to obtain a final diluted melphalan composition for the stability study.
  • the present invention is to provide a stable liquid pharmaceutical composition
  • a stable liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof, one or more solvents, one or more antioxidants, sodium chloride and optionally one or more pharmaceutically acceptable excipients
  • the said stable liquid pharmaceutical composition is first diluted with a diluent vehicle to obtain a stable ready to dilute pharmaceutical composition
  • the said stable ready to dilute pharmaceutical composition is further diluted with 0.9% sodium chloride solution and 5% dextrose solution to obtain a final diluted melphalan composition, wherein the said final diluted composition is stable for at least 2 hours when stored at 25 °C.
  • the present invention is to provide a stable liquid pharmaceutical composition
  • a stable liquid pharmaceutical composition comprising Melphalan or its pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients, wherein the said composition does not have more than 7.5% (w/w) of Impurity D when stored at 2-8 °C for at least 3 months.
  • the present invention is to provide a stable liquid pharmaceutical composition
  • a stable liquid pharmaceutical composition comprising Melphalan or its pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients, wherein the said composition does not have more than 2% (w/w) of Impurity D when stored at 2-8 °C for at least 3 months.
  • the present invention is to provide a stable liquid pharmaceutical composition
  • a stable liquid pharmaceutical composition comprising Melphalan or its pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients, wherein the said composition does not have more than 7.5% (w/w) of Impurity D when stored at 25 °C for at least 3 months.
  • the present invention is to provide a stable liquid pharmaceutical composition
  • a stable liquid pharmaceutical composition comprising Melphalan or its pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients, wherein the said composition does not have more than 2% (w/w) of Impurity D when stored at 25 °C for at least 3 months.
  • the present invention is to provide a stable liquid pharmaceutical composition
  • a stable liquid pharmaceutical composition comprising Melphalan or its pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients, wherein the said composition does not have more than 1% (w/w) of Impurity G when stored at 2-8 °C for at least 3 months.
  • the present invention is to provide a stable liquid pharmaceutical composition
  • a stable liquid pharmaceutical composition comprising Melphalan or its pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients, wherein the said composition does not have more than 0.6% (w/w) of Impurity G when stored at 2-8 °C for at least 3 months.
  • the present invention is to provide a stable liquid pharmaceutical composition
  • a stable liquid pharmaceutical composition comprising Melphalan or its pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients, wherein the said composition does not have more than 1% (w/w) of Impurity G when stored at 25 °C for at least 3 months.
  • the present invention is to provide a stable liquid pharmaceutical composition
  • a stable liquid pharmaceutical composition comprising Melphalan or its pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients, wherein the said composition does not have more than 0.6% (w/w) of Impurity G when stored at 25 °C for at least 3 months.
  • the present invention is to provide a stable, ready to dilute pharmaceutical composition
  • a stable, ready to dilute pharmaceutical composition comprising Melphalan or its pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients, wherein the said composition does not have more than 10% (w/w) of total impurity, when stored at 2-8 °C for at least 3 months.
  • the present invention is to provide a stable, ready to dilute pharmaceutical composition
  • a stable, ready to dilute pharmaceutical composition comprising Melphalan or its pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients, wherein the said composition does not have more than 5% of total impurity when stored at 2-8 °C for at least 3 months.
  • the present invention is to provide a stable, ready to dilute pharmaceutical composition
  • a stable, ready to dilute pharmaceutical composition comprising Melphalan or its pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients, wherein the said composition does not have more than 10% (w/w) of total impurity after being stored at 25 °C for at least 3 months.
  • the present invention is to provide a stable, ready to dilute pharmaceutical composition
  • a stable, ready to dilute pharmaceutical composition comprising Melphalan or its pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients, wherein the said composition does not have more than 5% of total impurity after being stored at 25 °C for at least 3 months.
  • the present invention is to provide a stable, ready to dilute pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof and pharmaceutically acceptable excipients, wherein the said composition is used for the treatment of multiple myeloma.
  • Example 1 Liquid melphalan composition
  • Manufacturing Process (a) mixing the solvents to obtain the clear solution;
  • step a) dissolving sodium chloride to the clear solution obtained in step a);
  • step b) dissolving one or more antioxidant to the solution obtained in step b);
  • step c) dissolving melphalan or its pharmaceutically acceptable salt in solution obtained in step c) and making up the volume.
  • step d) filtering the solution obtained in step d) and filling the filtered solution in suitable vials.
  • Example 2 Liquid melphalan composition
  • step a) mixing propylene glycol and polyethylene glycol 400 to obtain the clear solution; (b) dissolving sodium chloride to the clear solution obtained in step a);
  • step c) dissolving melphalan or its pharmaceutically acceptable salt in solution obtained in step c) and making up the volume.
  • step d) filtering the solution obtained in step d) and filling the filtered solution in suitable vials.
  • Example 3 Liquid melphalan composition
  • Manufacturing Process (a) mixing propylene glycol and polyethylene glycol 400 to obtain the clear solution;
  • step a) dissolving sodium chloride to the clear solution obtained in step a);
  • step c dissolving butylated hydroxytoluene and citric acid to the solution obtained in step b); (d) dissolving melphalan or its pharmaceutically acceptable salt in solution obtained in step c) and making up the volume. (e) filtering the solution obtained in step d) and filling the filtered solution in suitable vials.
  • Example 4 Liquid melphalan composition
  • step b dissolving sodium chloride to the clear solution obtained in step a); (c) dissolving alpha tocopherol to the solution obtained in step b);
  • step c) dissolving melphalan or its pharmaceutically acceptable salt in solution obtained in step c) and making up the volume.
  • step d) filtering the solution obtained in step d) and filling the filtered solution in suitable vials.
  • Example 5 Composition of diluent vehicle
  • Table 2 Stability data of diluted melphalan solution with diluent solution of 50 mg/mL SBE-CD in 0.9% Sodium chloride under different time interval at storage conditions of 2-8 °C and 25 °C
  • Table 3 Stability data of diluted melphalan solution with diluent solution of 200 mg/mL SBE-CD in 0.9% Sodium chloride under different time interval at storage condition of 2-8 °C and 25 °C.
  • Table 4 Stability data of diluted melphalan solution with diluent solution of 250 mg/mL SBE-CD in 0.9% Sodium chloride under different time interval at storage condition of 2-8 °C and 25 °C
  • Table 5 Stability data of diluted melphalan solution with diluent solution of 250 mg/mL SBE-CD and 4.5 mg/mL Sodium Citrate in 0.9% Sodium chloride under different time interval at storage condition of 2-8 °C and 25 °C
  • Table 6 Stability data of diluted melphalan solution with diluent solution of 250 mg/mL SBE-CD and 4.5 mg/mL Sodium Acetate in 0.9% Sodium chloride under different time interval at storage condition of 2-8 °C and 25 °C
  • the liquid pharmaceutical composition of melphalan diluted with diluent vehicle where in diluent vehicle contains 250 mg/mL SBE-CD and 4.5 mg/mL Sodium Acetate in 0.9% Sodium chloride to obtained ready to dilute melphalan composition and stored at 25 °C for 1 hour.
  • the resulted ready to dilute melphalan composition is further diluted with 0.9% Sodium Chloride and 5% dextrose injection to obtain 0.45 mg/mL concentration of final diluted melphalan composition.
  • the results of stability data for final diluted melphalan composition is summarized in below table.
  • the above data shows impurity D, impurity G and total impurity are not more than specified limit in the formulation, which is indicative of stability of melphalan HC1 in the drug product at 25 °C.
  • the stability data as mentioned above indicate that the liquid pharmaceutical composition of melphalan or its pharmaceutically acceptable salt thereof are stable. Further, the ready to dilute melphalan composition is stable for at least 72 hours at 2-8 °C and for at least 1 hours at 25 °C. Also, the final diluted melphalan composition obtained after dilution with 0.9% sodium chloride or 5% dextrose is stable for at least 2 hours at 25 °C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition pharmaceutique liquide stable comprenant du melphalan ou son sel pharmaceutiquement acceptable et un ou plusieurs excipients pharmaceutiquement acceptables, ladite composition pharmaceutique liquide stable étant d'abord diluée avec un véhicule diluant pour fournir une composition pharmaceutique stable, prête à diluer, de melphalan ou de ses sels pharmaceutiquement acceptables. Ladite composition pharmaceutique stable prête à diluer est en outre diluée pour obtenir une composition finale diluée de melphalan avant administration au patient qui en a besoin. En outre, la présente invention concerne un procédé de préparation de ladite composition et son utilisation pour le traitement du myélome multiple.
EP20886165.8A 2019-11-04 2020-11-04 Composition liquide de melphalan Pending EP4055005A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921044683 2019-11-04
PCT/IB2020/060334 WO2021090183A1 (fr) 2019-11-04 2020-11-04 Composition liquide de melphalan

Publications (2)

Publication Number Publication Date
EP4055005A1 true EP4055005A1 (fr) 2022-09-14
EP4055005A4 EP4055005A4 (fr) 2023-11-29

Family

ID=75849601

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20886165.8A Pending EP4055005A4 (fr) 2019-11-04 2020-11-04 Composition liquide de melphalan

Country Status (2)

Country Link
EP (1) EP4055005A4 (fr)
WO (1) WO2021090183A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116283627A (zh) * 2023-01-13 2023-06-23 深圳市江川医药技术有限公司 一种美法仑杂质g的合成方法
CN116102444A (zh) * 2023-01-16 2023-05-12 深圳振强生物技术有限公司 一种美法仑杂质d的纯化方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2060031C1 (ru) * 1993-05-27 1996-05-20 Онкологический научный центр Способ получения сарколизина для внутривенных инъекций
PL2434886T3 (pl) * 2009-05-29 2020-05-18 Cydex Pharmaceuticals, Inc. Kompozycje do wstrzykiwania melfalanu zawierające pochodną cyklodekstryny i sposoby ich wytwarzania i stosowania
US11020363B2 (en) * 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
US10537520B2 (en) * 2015-06-30 2020-01-21 Leiutis Pharmaceuticals Pvt. Ltd. Stable liquid formulations of melphalan
WO2017085696A1 (fr) * 2015-11-20 2017-05-26 Leiutis Pharmaceuticals Pvt Ltd Formulations parentérales de melphalan

Also Published As

Publication number Publication date
EP4055005A4 (fr) 2023-11-29
WO2021090183A1 (fr) 2021-05-14

Similar Documents

Publication Publication Date Title
US20220265829A1 (en) Formulations of bendamustine
KR101502533B1 (ko) 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
CN102421451B (zh) 苯达莫司汀环多糖组合物
CN101444510A (zh) 含有伏立康唑的药物制剂及其制备方法
US9375483B2 (en) Stable liquid pharmaceutical composition containing piroxicam or its pharmaceutically acceptable salt and hyaluronic acid or its pharmaceutically acceptable salt and the manufacturing method thereof
WO2017127835A2 (fr) Formulations aqueuses, et procédés de préparation et d'utilisation de celles-ci
KR102843054B1 (ko) 멜록시캄 조성물, 제제 및 이의 제조 방법 및 응용
WO2017002030A1 (fr) Formulations liquides stables de melphalan
CN107810000B (zh) 来氟米林的可注射药物组合物
EA034565B1 (ru) Композиции левосимендана для внутривенного введения в виде инфузии или инъекции и концентрата для инфузии
WO2020089826A1 (fr) Perfusion intraveineuse prête à l'emploi de brivaracétam ou d'un sel de celui-ci
CA3043979A1 (fr) Nouvelles formulations de composes de la famille des beta-lactamines substitues par une amidine, a base de cyclodextrines modifiees et d'agents acidifiants, leur preparation et leur utilisation en tant que compositions pharmaceutiques antimicrobiennes
WO2016116882A2 (fr) Nouvelles compositions de carfilzomib
WO2017013591A1 (fr) Formulation liquide stabilisée de lévothyroxine
EP4055005A1 (fr) Composition liquide de melphalan
TW201036639A (en) Pharmaceutical formulations of biodegradable biocompatible camptothecin-polymer conjugates
US11730815B2 (en) Stable liquid pharmaceutical compositions comprising bendamustine
US20210353633A1 (en) Cyclodextrin-based formulation of a bcl-2 inhibitor
WO2019097413A1 (fr) Compositions pharmaceutiques non aqueuses stables
EA008776B1 (ru) Жидкая стабильная композиция оксазафосфорина с месной
WO2017085696A1 (fr) Formulations parentérales de melphalan
WO2019130228A1 (fr) Compositions liquides stables de melphalan
CA3117511C (fr) Formulation à base de cyclodextrine d’un inhibiteur de bcl-2
EP4623897A1 (fr) Composition pharmaceutique contenant une concentration élevée d'opiransérine
WO2019094819A2 (fr) Systèmes d'administration par voie intraveineuse pour médicaments de chimiothérapie

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220530

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20231027

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/198 20060101ALI20231023BHEP

Ipc: A61K 47/20 20060101ALI20231023BHEP

Ipc: A61K 47/12 20060101ALI20231023BHEP

Ipc: A61K 47/10 20170101ALI20231023BHEP

Ipc: A61K 47/02 20060101ALI20231023BHEP

Ipc: A61P 35/00 20060101ALI20231023BHEP

Ipc: A61K 9/08 20060101ALI20231023BHEP

Ipc: C07C 229/36 20060101AFI20231023BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250314